NEW YORK (GenomeWeb News) – Response Genetics today said that it has signed definitive agreements with unnamed institutional investors for the sale of 932,805 shares of the firm's common stock through a registered direct offering.

The Los Angeles-based molecular diagnostics firm is selling the shares at $2.05 each, the stock's closing price on Thursday, and expects to raise gross proceeds of $1.9 million through the offering. It said it anticipates the offering will close on or around Sept. 25.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.